AIM: To examine the differences of clinical behaviors between hepatocellular carcinomas (HCC) and hepatoblastomas (HB) in children. METHODS: From 1979 to 1997, we collected 73 HCC and 54 HB from two major medical centers in Taiwan. Demog-raphic, laboratory and radiological data, and survival curves were statistically compared. RESULTS: HCC clinically differed from HB in mean age (10.6 vs 2.5 years; P<0.001), status of hepatitis B infection (56/56 vs 4/35, P<0.001) and accompanying liver cirrhosis (26/40 vs 0/30, P<0.001), portal vein thrombi (22/56 vs 5/38, P = 0.006) and para-aortic lymphadenopathy (10/56 vs 1/38, P = 0.026). Due to a higher recurrence rate (7/12 vs 2/13, P = 0.041), stage I HCC compared poorly in survivals with stage I HB (P = 0.0183). Chemotherapy could only benefit HB as evidenced by 66.7% of resectability conversion and improve survivals for advanced HB, even with unsuccessful conversion. The survival difference between stage I HB and advanced HB with delayed complete resection was of borderline insignificance (P = 0.0507). CONCLUSION: HCC and HB were preliminarily distinguishable by some clinical clues. Delayed resection after chemotherapy was only possible for HB. However, further studies are needed to strengthen our observation that appropriate reliance upon chemotherapy to subsequently resect advanced HB could achieve the comparable survival to that of stage I HB.
AIM: To examine the differences of clinical behaviors between hepatocellular carcinomas (HCC) and hepatoblastomas (HB) in children. METHODS: From 1979 to 1997, we collected 73 HCC and 54 HB from two major medical centers in Taiwan. Demog-raphic, laboratory and radiological data, and survival curves were statistically compared. RESULTS: HCC clinically differed from HB in mean age (10.6 vs 2.5 years; P<0.001), status of hepatitis B infection (56/56 vs 4/35, P<0.001) and accompanying liver cirrhosis (26/40 vs 0/30, P<0.001), portal vein thrombi (22/56 vs 5/38, P = 0.006) and para-aortic lymphadenopathy (10/56 vs 1/38, P = 0.026). Due to a higher recurrence rate (7/12 vs 2/13, P = 0.041), stage I HCC compared poorly in survivals with stage I HB (P = 0.0183). Chemotherapy could only benefit HB as evidenced by 66.7% of resectability conversion and improve survivals for advanced HB, even with unsuccessful conversion. The survival difference between stage I HB and advanced HB with delayed complete resection was of borderline insignificance (P = 0.0507). CONCLUSION: HCC and HB were preliminarily distinguishable by some clinical clues. Delayed resection after chemotherapy was only possible for HB. However, further studies are needed to strengthen our observation that appropriate reliance upon chemotherapy to subsequently resect advanced HB could achieve the comparable survival to that of stage I HB.
Authors: T Sakairi; K Kobayashi; K Goto; M Okada; M Kusakabe; T Tsuchiya; J Sugimoto; F Sano; M Mutai Journal: Toxicol Pathol Date: 2001 Jul-Aug Impact factor: 1.902
Authors: Markus Peck-Radosavljevic; Johann Deutsch; Peter Ferenci; Ivo Graziadei; Harald Hofer; Heidemarie Holzmann; Wolf-Dietrich Huber; Herman Laferl; Andreas Maieron; Rudolf Stauber; Wolfgang Vogel Journal: Wien Klin Wochenschr Date: 2010-05-04 Impact factor: 1.704
Authors: Julia E Heck; Chia-Kai Wu; Xiwen Huang; Kara W Chew; Myron Tong; Noah Federman; Beate Ritz; Onyebuchi A Arah; Chung-Yi Li; Fei Yu; Jorn Olsen; Johnni Hansen; Pei-Chen Lee Journal: Int J Epidemiol Date: 2022-05-09 Impact factor: 9.685
Authors: Jane Liaw; Guillermo Marshall; Yan Yuan; Catterina Ferreccio; Craig Steinmaus; Allan H Smith Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254